Combination of CTL-associated antigen-4 blockade and depletion of CD25 + regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer

Scandinavian Journal of Immunology

Volumn 71, Issue 2, 2010, Pages 70-82

  Saha, Asim ^a,b   Chatterjee, S K ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AUTOANTIBODY; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD25 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; DNA ANTIBODY; GAMMA INTERFERON; HLA A2 ANTIGEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T CELL DEPLETION; TRANSGENICS; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL SEPARATION; COLONIC NEOPLASMS; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HLA-A2 ANTIGEN; IMMUNOTHERAPY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE DEPLETION; MICE; MICE, TRANSGENIC; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 75149139044     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2009.02355.x     Document Type: Article

References (52)

1. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R. Strategies for immunotherapy of cancer. Adv Immunol 2000 75: 235 282.
2. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994 12: 337 365.
3. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998 4: 1321 1324.
4. + T cells. J Exp Med 2003 198: 569 580.
5. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006 16: 115 123.
6. Sakaguchi S, Toda M, Asano M, Itoh M, Morse SS, Sakaguchi N. T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J Autoimmun 1996 9: 211 220. (Pubitemid 26163865)
7. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998 160: 1212 1218.
8. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999 163: 5211 5218.
9. + T-cell-dependent immune defense of B16 melanoma. Cancer Res 2001 61: 8643 8646.
10. Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res 2005 11: 4533 4544.
11. Nanni P, Nicoletti G, Palladini A et al. Antimetastatic activity of a preventive cancer vaccine. Cancer Res 2007 67: 11037 11044.
12. Delluc S, Hachem P, Rusakiewicz S et al. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of long-lasting T cell response. Cancer Immunol Immunother 2009 58: 1669 1677.
13. + T cell responses. J Exp Med 2002 196: 1585 1592.
14. + T cells. Proc Natl Acad Sci USA 2002 99: 8832 8837.
15. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002 3: 611 618.
16. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immuno-therapy. Nat Immunol 2001 2: 293 299.
17. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996 271: 1734 1736.
18. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 1998 95: 10067 10071.
19. Espenschied J, Lamont J, Longmate J et al. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 2003 170: 3401 3407.
20. Demaria S, Kawashima N, Yang AM et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005 11: 728 734.
21. Kocak E, Lute K, Chang X et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 2006 66: 7276 7284.
22. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999 190: 355 366.
23. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997 90: 3245 3287.
24. Engleman EG. Dendritic cell-based cancer immunotherapy. Semin Oncol 2003 30 (3 Suppl. 8 23 9.
25. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest 2003 21: 873 886.
26. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991 5: 344 366.
27. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 2002 20: 2197 2207.
28. Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Cancer Res 2007 67: 2881 2892.
29. Saha A, Bhattacharya-Chatterjee M, Foon KA, Celis E, Chatterjee SK. Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice. Int J Cancer 2009 124: 877 888.
30. Clarke P, Mann J, Simpson JF, Rickard-Dickson K, Primus FJ. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 1998 58: 1469 1477.
31. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995 87: 982 990.
32. Lowenthal JW, Corthesy P, Tougne C, Lees R, MacDonald HR, Nabholz M. High and low affinity IL-2 receptors: analysis by IL-2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. J Immunol 1985 135: 3988 3994.
33. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994 1: 405 413.
34. Saha A, Chatterjee SK, Foon KA et al. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res 2004 64: 4995 5003.
35. Bhattacharya-Chatterjee M, Mukherjee S, Biddle W, Foon KA, Kohler H. Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. J Immunol 1990 145: 2758 2765.
36. Lu J, Higashimoto Y, Appella E, Celis E. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol 2004 172: 4575 4582.
37. Wang J, Lo JC, Foster A et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J Clin Invest 2001 108: 1771 1780.
38. + T cells. J Immunol 1995 155: 1873 1883.
39. -) to TCR/CD8 signaling in response to antigen. J Immunol 1998 160: 3236 3243.
40. Yu Z, Restifo NP. Cancer vaccines: progress reveals new complexities. J Clin Invest 2002 110: 289 294.
41. van Elsas A, Sutmuller RP, Hurwitz AA et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 2001 194: 481 489.
42. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003 100: 8372 8377.
43. Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005 12: 1005 1016.
44. Sutmuller RP, van Duivenvoorde LM, van Elsas A et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001 194: 823 832.
45. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005 175: 7746 7754.
46. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006 116: 1935 1945.
47. Takahashi T, Tagami T, Yamazaki S et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000 192: 303 310.
48. Farrar MA, Schreiber RD. The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol 1993 11: 571 611.
49. Mazzolini G, Narvaiza I, Martinez-Cruz LA et al. Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFN-γ-induced apoptosis. Gene Ther 2003 10: 1067 1078.
50. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity 1994 1: 447 456.
51. Houghton AN, Thomson TM, Gross D, Oettgen HF, Old LJ. Surface antigens of melanoma and melanocytes: specificity of induction of Ia antigens by human γ-interferon. J Exp Med 1984 160: 255 269. (Pubitemid 14089794)
52. Coughlin CM, Salhany KE, Gee MS et al. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998 9: 25 34.